Revvity signed an agreement to acquire Human Cell Design (HCD), a France-based developer of human cell models used in preclinical research. Revvity said the deal is expected to add HCD’s human pancreatic beta cell models to its Life Sciences portfolio, including the EndoC-βH5 platform. The acquisition is positioned to support drug discovery and screening in diabetes and obesity research, with anticipated cross-usage alongside Revvity’s assay and screening workflows. The transaction is targeted to close in Q4 2026.